Racecadotril induced bilateral uveal effusion: a case report
Abstract
Background: Uveal effusion is a sight threatening condition, due to possible acute angle-closure glaucoma and maculopathy. We present a case of bilateral uveal effusion after taking racecadotril, an enkephalinase inhibitor used as a medical treatment for diarrhea. Uveal effusion after the use of racecadotril has not been described in literature.
Case presentation: A 76-year-old woman presented with blurred vision in both eyes. Fundoscopy and B-scan ultrasound showed bilateral choroidal effusion. The anterior chamber was narrow, but the intra ocular pressure remained normal. The medication review showed that the only recently added medication was racecadotril. Other potential causes of uveal effusion were excluded. Topical steroids and atropine were started. After cessation of racecadotril, a complete resolution of the uveal effusion was observed.
Conclusions: This case of bilateral uveal effusion was probably caused by racecadotril, since this was the only recently started drug, and we observed a complete resolution of the effusion after cessation of the drug. It is possible that the increase in enkephalins caused by racecadotril intake, leads to changes in the choroid, causing choroidal effusion. It is important to recognize uveal effusion as a rare side effect of racecadotril, because of its possible sight threatening character.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.